With the widespread COVID-19, people in medical and pharmaceutical industries are desperately trying to invent vaccines. On August 11th, Russia first launched the world’s first COVID-19 vaccine, Sputnik V, funded by the Russian Direct Investment Fund (RDIF). The Global Times reported that currently, the RDIF is in talks with Chinese partners for the mass production of Sputnik V in November. Since China has the ability to produce the vaccine and supply it to Asia, the production of Sputnik will begin soon when Chinese partners complete the technology transfer. However, questions and concerns over the efficacy and safety of the vaccine have come to the surface. In general, vaccines should undergo testing and the approval process before they are launched. Clinical trials are three-phase processes that experiment with vaccines by giving medicines to test subjects. In Phase III, the vaccine is given to thousands of people to test for efficacy and safety. Sputnik V, however, did not even undergo Phase III and sufficient testing. The participants were only 38 and 78 in each Phase I and II, while another vaccine Moderna was tested towards 600 participants in Phase II. Despite concerns over safety, Russia has received preliminary applications for Sputnik V from 20 countries according to Dmitriev, the CEO of the RDIF. Also, Denis Manturov, Minister of Industry and Trade of the Russian Federation, notes that the exportation of Sputnik V may begin in the spring of 2021.